Dr Ulf Grawunder | Chief Executive Officer & Founder
NBE Therapeutics

Dr Ulf Grawunder, Chief Executive Officer & Founder, NBE Therapeutics

Ulf Grawunder is founder and CEO of NBE-Therapeutics, a Swiss Biotech company incorporated in 2012, which focuses on the development of "next-generation" antibody-drug conjugates for cancer therapy. 
Prior to that, Ulf had co-founded 4-Antibody in 2004, a Swiss therapeutic antibody engineering company, where he initially served as CEO and later as CSO, until the company was sold to US-based Agenus in 2013. Ulf is a Biochemist who did his PhD in area of B cell Immunology at the Basel Institute for Immunology. After this he did several years of post-doctoral research at Washington University School of Medicine, St. Louis, and the University of Southern California, Los Angeles, and continued as principal investigator again at the Basel Institute for Immunology, and the University of Basel, Switzerland, before he started his first Biotech company.
Ulf is member of a number of national and international boards of for profit and non-profit organizations, including the scientific advisory board of the Bavarian Immunotherapies Network, BayImmuNet, Germany (www.bayimmunet.de), and the Board of the Swiss Biotech Association (SBA, www.swissbiotech.org).


EAC 2017 Day 2, Wednesday 1st November 2017 @ 15:15

Preclinical validation of site-specifically conjugated ADCs with potent anthracycline payloads in solid and hematologic tumor models

  • Rationale of site-specifically conjugated ADCs
  • Validation of a novel ultrapotent anthracycline-toxin in ADCs
  • Preclinical validation of NBE’s lead ADCs in preclinical tumor models
  • Characterization of the immune-oncology function of NBE’s ADCs

back to speakers